Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Citi
Cerilliant
UBS
Harvard Business School
Healthtrust
Accenture
Colorcon
McKinsey
Queensland Health

Generated: October 17, 2017

DrugPatentWatch Database Preview

ENJUVIA Drug Profile

« Back to Dashboard

What is the patent landscape for Enjuvia, and what generic Enjuvia alternatives are available?

Enjuvia is a drug marketed by Teva Branded Pharm and is included in one NDA. There are two patents protecting this drug.

This drug has seventeen patent family members in nine countries.

The generic ingredient in ENJUVIA is estrogens, conjugated synthetic b. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the estrogens, conjugated synthetic b profile page.

Summary for Tradename: ENJUVIA

US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list2
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ENJUVIA at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-001Dec 20, 2004DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-002Dec 20, 2004DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-004May 10, 2004DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-001Dec 20, 2004DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-002Dec 20, 2004DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-005Apr 27, 2007DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-005Apr 27, 2007DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-004May 10, 2004DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-003May 10, 2004DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-003May 10, 2004DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: ENJUVIA

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
► Subscribe
ENJUVIA
► Subscribe

Non-Orange Book Patents for Tradename: ENJUVIA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,749,989Estrogenic compounds, methods of using and methods of administering the same► Subscribe
6,250,127 Heat-dissipating aluminum silicon carbide composite manufacturing method► Subscribe
7,179,799(3) and (6) substituted estrogenic compounds► Subscribe
7,459,445Estrogenic compounds and topical pharmaceutical formulations of the same► Subscribe
7,989,436Estrogenic compounds and pharmaceutical formulations comprising the same► Subscribe
6,844,334 (3) and (6) substitued estrogenic compounds► Subscribe
8,227,454Estrogenic compounds, pharmaceutical compositions and formulations comprising the same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ENJUVIA

Country Document Number Estimated Expiration
European Patent Office1267852► Subscribe
Canada2402667► Subscribe
MexicoPA02008856► Subscribe
Australia4733701► Subscribe
European Patent Office1263770► Subscribe
Japan2004500396► Subscribe
Austria377605► Subscribe
Australia2001245417► Subscribe
South Korea20070045364► Subscribe
World Intellectual Property Organization (WIPO)0168074► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Argus Health
Covington
Dow
Medtronic
Fuji
McKinsey
Mallinckrodt
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot